Clinical trials: Epilepsy (treatment Refractory)
Epilepsy, Unspecified, Refractory (Medically)
The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy
Many families of children with medically refractory epilepsy are choosing to use medicinal cannabinoids (MCBD) as an adjunctive alternative treatment option. The safety, tolerability and efficacy of these products are not known.
- Trial name
- NCT02523183
- Testing
- Medical Cannabis
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Colorado, Denver
Epilepsy
Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study
The purpose of this study is to determine whether omega-3 is effective in the treatment of medically intractable epilepsy as adjunctive therapy.
- Trial name
- NCT02899741
- Testing
- Omega-3
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Epilepsia Partialis Continua, Status Epilepticus
Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy
The purpose of this study is to assess the effects of repetitive transcranial magnetic stimulation (rTMS) as a treatment for Epilepsia Partialis Continua (EPC) or refractory Status Epilepticus (SE), when standard clinical…
- Trial name
- NCT02560597
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Belgium
- Volunteers
- 4 people
- Sponsor
- University Hospital, Ghent
Inborn Errors of Metabolism, Epilepsy (Treatment Refractory)
Metabolites in Blood and Breath in Metabolic Conditions
In patients with inborn errors of metabolism (IEM) and in those requiring a ketogenic diet for the treatment of medical conditions, relevant biochemical analytes are routinely and regularly measured in venous or capillary blood…
- Trial name
- NCT07704606
- Testing
- Observational Study
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Children's Hospital, Zurich
Refractory Epilepsy, SYNGAP1 Encephalopathy
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
This study is a pilot non-controlled clinical trial with adjunctive fenfluramine for the treatment of five different types of developmental and epileptic encephalopathies (DEEs) focused on epileptic and "non-epileptic outcomes"…
- Conditions
- Refractory Epilepsy, SYNGAP1 Encephalopathy, STXBP1 Encephalopathy With Epilepsy, Inv Dup(15) Encephalopathy
- Trial name
- FENDEEP (NCT05232630)
- Testing
- Fenfluramine
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Hospital Ruber Internacional
Epilepsy, Depressions, Refractory
Low Frequency TMS for Depression in Epilepsy
The purpose of this study is to determine if low-frequency transcranial magnetic stimulation (TMS) is safe and feasible for treating depressive symptoms in patients with epilepsy.
- Trial name
- LFTMS (NCT03105700)
- Testing
- Transcranial Magnetic Stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Epilepsy (Treatment Refractory)
Epilepsy Cycles Longitudinal Monitoring to Inform Personalized Seizure-risk Estimation (ECLIPSE)
The occurrence of seizures in epilepsy is not entirely random. Temporal patterns that organize the occurrence of seizures over weeks and months were previously unraveled using intracranial EEG System (IEEG) that monitors…
- Trial name
- ECLIPSE (NCT06952764)
- Testing
- Seizure risk forecast, Control seizure risk forecast
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Focal Epilepsy
Prospective Open-label Evaluation of Cenobamate Adjunctive Treatment of Adults With Refractory Focal Epilepsy
To evaluate the efficacy, safety and tolerability of cenobamate as adjunctive treatment of refractory focal epilepsy
- Trial name
- NCT04879433
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mid-Atlantic Epilepsy and Sleep Center, LLC
Epilepsy Intractable
Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs
This is an open label, randomized, prospective study of the impact on healthcare utilization of a surface Electromyography (sEMG) based seizure monitoring and alerting system for Veterans with seizures with upper extremity motor…
- Trial name
- NCT03741192
- Testing
- SPEAC System
- Volunteers
- 58 people
- Sponsor
- Brain Sentinel
Epilepsy (treatment Refractory)
Percutaneous Repair for Drug - Resistant Epilepsy by Intervention of Closing the Patent Foramen Ovale（PREDICT-PFO Trial）
Patent foramen ovale (PFO) is the most common cause of right-to-left shunt (RLS) in the adult heart, with a prevalence of approximately 25% in the general population.
- Trial name
- PREDICT-PFO (NCT06863350)
- Testing
- patent foramen ovale closure
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sichuan University
Partial Epilepsy in Children and Adolescents
Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children
The purpose of this study is to examine the efficacy and safety of Eslicarbazepine acetate (BIA 2-093) when given with other anti-epileptic drugs to treat children with partial seizures whose condition has not been controlled by…
- Trial name
- NCT00988156
- Testing
- Eslicarbazepine acetate (BIA 2-093), Eslicarbazepine acetate
- Where
- 91 sites in Austria, Bosnia and Herzegovina and 19 more
- Volunteers
- 304 people
- Sponsor
- Bial - Portela C S.A.
Epilepsy
A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
- Trial name
- NCT00175825
- Testing
- Brivaracetam
- Where
- 42 sites in United States, Brazil and 2 more
- Volunteers
- 210 people
- Sponsor
- UCB Pharma
Epilepsy (Treatment Refractory)
A Study to Evaluate the Safety and Effectiveness of Magnetic Resonance-Guided Ultrasound Ablation of the Anterior Nucleus of Thalamus for the Treatment of Drug-resistant Epilepsy.
The study "Safety and Efficacy Evaluation of MR-Guided Focused Ultrasound Anterior Thalamic Nucleus Ablation for Drug-Resistant Epilepsy" from Chinese PLA General Hospital, is a single-center, prospective, single-arm study.
- Trial name
- NCT07249190
- Testing
- MR-guided Focused Ultrasound Therapy
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Focal Epilepsy, Generalized Seizure
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Trial name
- FORESITE (NCT07012148)
- Testing
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Refractory Status Epilepticus
Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus
This project is aiming to better understand the use of perampanel as an appropriate standard-of-care therapy for treatment refractory status epilepticus (RSE), to identify determinants of outcomes, and establish safety.
- Trial name
- NCT05684978
- Testing
- Perampanel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wayne State University
Epileptic Spasms, Failed Hormonal Therapy
Modified Atkins Diet Versus Topiramate In Children With Epileptic Spasms Refractory To Hormonal Treatment: A Randomized Open-Label Study
This study has been planned to compare the efficacy and tolerability of topiramate, a commonly used second line agent, with modified Atkins diet in children with epileptic spasms refractory to hormonal treatment, in a randomized…
- Trial name
- TOPAMAD (NCT05958160)
- Testing
- Modified Atkins diet, Topiramate
- Where
- India
- Volunteers
- 70 people
- Sponsor
- Lady Hardinge Medical College
Epilepsy
E2007 Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
The primary objective of this study is to determine the maximal tolerated dose (MTD) of E2007 given twice daily (bid) or once a day (qd) in patients with refractory partial-onset seizures (including secondarily generalized…
- Trial name
- NCT00144690
- Testing
- E2007 (perampanel)
- Where
- 5 sites in United States
- Sponsor
- Eisai Inc.
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in patients with difficult to control partial onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236691
- Testing
- topiramate
- Volunteers
- 188 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Partial Epilepsy
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
- Trial name
- NCT00908349
- Testing
- Oxcarbazepine XR
- Where
- 58 sites in United States, Bulgaria and 6 more
- Volunteers
- 214 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Tuberous Sclerosis Complex-associated Refractory Seizures
A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures
This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.
- Trial name
- EXIST-3 (NCT01713946)
- Testing
- RAD001, Antiepileptic drug (1 to 3 only), open label RAD001 (only used for post-extension phase)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 366 people
- Sponsor
- Novartis Pharmaceuticals